Taysha Gene Therapies, Inc. (TSHA)
Nasdaq · Biological Products, (No Diagnostic Substances) · Manufacturing · CIK 1806310 · fiscal year ends in Dec
Closing price $4.22 on 29 Oct 2026; 52-week range $3.50 to $6.98.
Key figures
The last twelve months reported, with the latest price and balance sheet.
- Revenue, last twelve months
- $5.5M
- Revenue growth
- -32.3%
- Net income, last twelve months
- -$149.6M
- Earnings per share
- -$0.42
- Operating margin
- -2792.3%
- Net margin
- -2728.0%
- Return on equity
- -38.6%
- Market value
- $1.4B
- Cash
- $455.4M
- Debt
- $49.3M
- Debt to equity
- 0.13
- Shares outstanding
- 325.3M
Financial statements
Revenue, profit and cash flow by fiscal year, each year linked to its annual report.
| Fiscal year | Year end | Revenue | Operating income | Net income | EPS | Free cash flow | Filing |
|---|---|---|---|---|---|---|---|
| FY2025 | 31 Dec 2025 | $9.8M | -$110.5M | -$109.0M | -$0.34 | -$93.8M | 10-K filed 19 Mar 2026 |
| FY2024 | 31 Dec 2024 | $8.3M | -$91.5M | -$89.3M | -$0.36 | -$81.6M | 10-K filed 26 Feb 2025 |
| FY2023 | 31 Dec 2023 | $15.5M | -$72.4M | -$111.6M | -$0.96 | -$76.9M | 10-K filed 19 Mar 2024 |
| FY2022 | 31 Dec 2022 | $2.5M | -$162.4M | -$166.0M | -$3.78 | -$109.0M | 10-K filed 28 Mar 2023 |
By quarter
| Quarter | Quarter end | Revenue | Net income | EPS |
|---|---|---|---|---|
| Q2 FY2026 | 30 Jun 2026 | $0 | -$46.6M | -$0.13 |
| Q1 FY2026 | 31 Mar 2026 | $0 | -$42.4M | -$0.12 |
| Q4 FY2025 | 31 Dec 2025 | $5.5M | -$27.9M | -$0.08 |
| Q3 FY2025 | 30 Sep 2025 | $0 | -$32.7M | -$0.09 |
| Q2 FY2025 | 30 Jun 2025 | $2.0M | -$26.9M | -$0.09 |
| Q1 FY2025 | 31 Mar 2025 | $2.3M | -$21.5M | -$0.08 |
| Q4 FY2024 | 31 Dec 2024 | $2.0M | -$18.8M | -$0.07 |
| Q3 FY2024 | 30 Sep 2024 | $1.8M | -$25.5M | -$0.10 |
Company events
The newest 8-K filings of 90 held.
| Filed | Form | Event | Items |
|---|---|---|---|
| 11 Aug 2026 | 8-K | Results | 2.02, 9.01 |
| 25 Jun 2026 | 8-K | Material agreement, Other events | 1.01, 8.01, 9.01 |
| 22 Jun 2026 | 8-K | Investor update, Other events | 7.01, 8.01, 9.01 |
| 2 Jun 2026 | 8-K | Shareholder vote | 5.07 |
| 6 May 2026 | 8-K | Results | 2.02, 9.01 |
| 19 Mar 2026 | 8-K | Results | 2.02, 9.01 |
| 4 Nov 2025 | 8-K | Results, Material agreement | 1.01, 2.02, 9.01 |
| 16 Oct 2025 | 8-K | Other events | 8.01, 9.01 |
| 9 Oct 2025 | 8-K | Other events | 8.01, 9.01 |
| 2 Oct 2025 | 8-K | Other events | 8.01, 9.01 |
| 12 Aug 2025 | 8-K | Results | 2.02, 9.01 |
| 3 Jun 2025 | 8-K | Shareholder vote, Bylaws or fiscal year change | 5.03, 5.07, 9.01 |
Every filing
The newest filings with the SEC of 182 held.
| Filed | Form | Period |
|---|---|---|
| 11 Aug 2026 | 10-Q | 30 Jun 2026 |
| 11 Aug 2026 | 8-K | 11 Aug 2026 |
| 25 Jun 2026 | 8-K | 24 Jun 2026 |
| 22 Jun 2026 | 8-K | 22 Jun 2026 |
| 2 Jun 2026 | 8-K | 1 Jun 2026 |
| 6 May 2026 | 10-Q | 31 Mar 2026 |
| 6 May 2026 | 8-K | 6 May 2026 |
| 22 Apr 2026 | ARS | 31 Dec 2025 |
| 22 Apr 2026 | DEFA14A | – |
| 22 Apr 2026 | DEF 14A | 1 Jun 2026 |
| 19 Mar 2026 | 10-K | 31 Dec 2025 |
| 19 Mar 2026 | 8-K | 19 Mar 2026 |
Insider trades
Form 4 trades by officers, directors and 10% owners, last 12 months.
| Traded | Insider | Type | Shares | Price | Value | Held after | Form 4 |
|---|---|---|---|---|---|---|---|
| 10 Jul 2026 | Nagendran Sukumar, President and Head of R&D | Sale under a trading plan | 200,000 | $6.24 | $1.2M | 936,410 | 10 Jul 2026 |
| 10 Apr 2026 | Nagendran Sukumar, President and Head of R&D | Sale under a trading plan | 200,000 | $4.46 | $892.0K | 1,136,410 | 13 Apr 2026 |
| 4 Feb 2026 | Alam Kamran, CHIEF FINANCIAL OFFICER | Sale outside a trading plan | 1,655 | $4.52 | $7.5K | 1,442,131 | 6 Feb 2026 |
| 26 Jan 2026 | Nagendran Sukumar, President and Head of R&D | Sale outside a trading plan | 26,918 | $4.61 | $124.1K | 1,317,389 | 27 Jan 2026 |
| 26 Jan 2026 | Nolan Sean P., Chief Executive Officer | Sale outside a trading plan | 41,312 | $4.61 | $190.4K | 2,908,257 | 27 Jan 2026 |
| 26 Jan 2026 | Alam Kamran, CHIEF FINANCIAL OFFICER | Sale outside a trading plan | 23,849 | $4.61 | $109.9K | 1,443,786 | 27 Jan 2026 |
| 23 Jan 2026 | Nagendran Sukumar, President and Head of R&D | Sale outside a trading plan | 89,132 | $4.75 | $423.4K | 1,344,307 | 27 Jan 2026 |
| 23 Jan 2026 | Nolan Sean P., Chief Executive Officer | Sale outside a trading plan | 136,789 | $4.75 | $649.7K | 2,949,569 | 27 Jan 2026 |
| 23 Jan 2026 | Alam Kamran, CHIEF FINANCIAL OFFICER | Sale outside a trading plan | 78,968 | $4.75 | $375.1K | 1,467,635 | 27 Jan 2026 |
| 12 Jan 2026 | Nagendran Sukumar, President and Head of R&D | Sale under a trading plan | 200,000 | $4.71 | $942.0K | 1,006,439 | 14 Jan 2026 |
| 1 Dec 2025 | Nagendran Sukumar, President and Head of R&D | Sale outside a trading plan | 260,047 | $4.51 | $1.2M | 1,006,439 | 1 Dec 2025 |
| 28 Nov 2025 | Nagendran Sukumar, President and Head of R&D | Sale outside a trading plan | 110,125 | $4.75 | $523.1K | 1,006,439 | 1 Dec 2025 |
Planned insider sales
Form 144 notices, filed when the sell order goes to the broker.
| Filed | Seller | Shares | Value | Planned sale |
|---|---|---|---|---|
| 10 Jul 2026 | Nagendran Sukumar, Officer | 200,000 | $1.3M | 10 Jul 2026 |
| 10 Apr 2026 | Nagendran Sukumar, Officer | 200,000 | $926.0K | 10 Apr 2026 |
| 27 Feb 2026 | Rumana Haque-Ahmed, Officer | 2,405 | $11.0K | 27 Feb 2026 |
| 4 Feb 2026 | Rumana Haque-Ahmed, Officer | 697 | $3.3K | 4 Feb 2026 |
| 4 Feb 2026 | Fred Porter, Affiliate-Chief of Staff & Tech.Op.Officer | 889 | $4.2K | 4 Feb 2026 |
| 4 Feb 2026 | Emily McGinnis, Affiliate-Chief Pat. Adv. & Ext. Aff. Off. | 901 | $4.3K | 4 Feb 2026 |
| 4 Feb 2026 | Sean McAuliffe, Affiliate - Chief Business Officer | 914 | $4.3K | 4 Feb 2026 |
| 4 Feb 2026 | Kamran Alam, Officer | 1,655 | $7.8K | 4 Feb 2026 |
| 23 Jan 2026 | Rumana Haque-Ahmed, Officer | 30,052 | $153.0K | 23 Jan 2026 |
| 23 Jan 2026 | Emily McGinnis, Affiliate-Chief Pat. Adv. & Ext. Aff. Off. | 32,077 | $163.3K | 23 Jan 2026 |
Large holders
Schedule 13D and 13G filings by holders of more than 5% of the voting shares.
| Filed | Holder | Schedule | Stake | Shares |
|---|---|---|---|---|
| 14 Aug 2026 | RA Capital Management, L.P. | 13G amended | 9.9% | 32.9M |
| 13 Aug 2026 | Morgan Stanley | 13G amended | 5.1% | 16.2M |
| 15 May 2026 | RTW Investments, LP | 13G amended | 7% | 20.7M |
| 15 May 2026 | Vestal Point Capital, LP | 13G amended | 6.3% | 18.0M |
| 17 Feb 2026 | RTW Investments, LP | 13G amended | 8.3% | 23.4M |
| 17 Feb 2026 | Vestal Point Capital, LP | 13G | 5% | 13.8M |
| 5 Feb 2026 | FMR LLC | 13G amended | 4.9% | 13.5M |
| 21 Jan 2026 | BlackRock, Inc. | 13G amended | 6.5% | 17.9M |
| 14 Nov 2025 | RA Capital Management, L.P. | 13G amended | 9.9% | 27.7M |
| 14 Nov 2025 | Octagon Capital Advisors LP | 13G amended | 3.3% | 9.1M |
Short interest
Shares sold short and not yet bought back, on each FINRA settlement date.
| Settlement | Shares short | Change | Days to cover |
|---|---|---|---|
| 15 Oct 2026 | 51.2M | -6.85% | 11.56 |
| 30 Sep 2026 | 55.0M | +7.03% | 11.15 |
| 15 Sep 2026 | 51.4M | +9.84% | 18.78 |
| 31 Aug 2026 | 46.8M | +0.13% | 19.4 |
| 14 Aug 2026 | 46.7M | +0.1% | 17.42 |
| 31 Jul 2026 | 46.7M | +3.09% | 19 |
| 15 Jul 2026 | 45.3M | +9.41% | 13.34 |
| 30 Jun 2026 | 41.4M | +6.89% | 8.06 |
Funds that hold it
From each fund's latest Form 13F.
230 funds held it at 30 Jun 2026: 137 added and 41 trimmed in the quarter. The largest:
| Fund | Shares | Value | Change in the quarter |
|---|---|---|---|
| Avoro Capital Advisors LLC | 23,888,888 | $162.7M | +2,188,888 |
| Ra Capital Management, L.P. | 23,555,648 | $160.4M | 0 |
| Goldman Sachs Group Inc. | 22,713,118 | $154.7M | +343,473 |
| BlackRock, Inc. | 20,691,927 | $140.9M | +2,326,319 |
| Vestal Point Capital, LP | 19,415,000 | $132.2M | +1,415,000 |
| Morgan Stanley | 16,487,479 | $112.3M | -1,477,892 |
| RTW Investments, LP | 13,560,258 | $92.3M | -119,990 |
| FMR LLC | 13,336,413 | $90.8M | -984,842 |
| Vanguard Capital Management LLC | 12,478,595 | $85.0M | +2,247,093 |
| State Street Corp. | 11,421,920 | $77.8M | +212,842 |
Peers
Companies in the same industry.
- Amgen Inc. (AMGN): revenue $38.1B, market value $249.1B
- Gilead Sciences, Inc. (GILD): revenue $30.5B, market value $205.5B
- Moderna, Inc. (MRNA): revenue $2.2B, market value $88.9B
- argenx SE (ARGX): revenue $4.2B, market value $55.5B
- Biogen Inc. (BIIB): revenue $10.3B, market value $36.9B
- BioNTech SE (BNTX): revenue $3.2B, market value $22.4B
- Exelixis, Inc. (EXEL): revenue $2.5B, market value $16.2B
- Halozyme Therapeutics, Inc. (HALO): revenue $1.7B, market value $15.0B
- Neurocrine Biosciences Inc. (NBIX): revenue $3.4B, market value $14.9B
- Bio-Techne Corp. (TECH): revenue $1.2B, market value $11.3B